SG11201407220YA - N-alkyltriazole compounds as lpar antagonists - Google Patents

N-alkyltriazole compounds as lpar antagonists

Info

Publication number
SG11201407220YA
SG11201407220YA SG11201407220YA SG11201407220YA SG11201407220YA SG 11201407220Y A SG11201407220Y A SG 11201407220YA SG 11201407220Y A SG11201407220Y A SG 11201407220YA SG 11201407220Y A SG11201407220Y A SG 11201407220YA SG 11201407220Y A SG11201407220Y A SG 11201407220YA
Authority
SG
Singapore
Prior art keywords
international
new jersey
compounds
drive
designated states
Prior art date
Application number
SG11201407220YA
Other languages
English (en)
Inventor
Stephen Deems Gabriel
Matthew Michael Hamilton
Matthew C Lucas
Yimin Qian
Achyutharao Sidduri
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48628667&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201407220Y(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of SG11201407220YA publication Critical patent/SG11201407220YA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
SG11201407220YA 2012-06-20 2013-06-17 N-alkyltriazole compounds as lpar antagonists SG11201407220YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261661961P 2012-06-20 2012-06-20
PCT/EP2013/062461 WO2013189864A1 (en) 2012-06-20 2013-06-17 N-alkyltriazole compounds as lpar antagonists

Publications (1)

Publication Number Publication Date
SG11201407220YA true SG11201407220YA (en) 2014-12-30

Family

ID=48628667

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201407220YA SG11201407220YA (en) 2012-06-20 2013-06-17 N-alkyltriazole compounds as lpar antagonists

Country Status (22)

Country Link
US (1) US9321738B2 (pt)
EP (1) EP2864300A1 (pt)
JP (1) JP2015520202A (pt)
KR (1) KR20150021057A (pt)
CN (1) CN104411692A (pt)
AU (1) AU2013279512A1 (pt)
BR (1) BR112014030685A2 (pt)
CA (1) CA2869541A1 (pt)
CL (1) CL2014003243A1 (pt)
CO (1) CO7131358A2 (pt)
CR (1) CR20140525A (pt)
EA (1) EA201492285A1 (pt)
HK (1) HK1206342A1 (pt)
IL (1) IL236088A0 (pt)
IN (1) IN2014DN09348A (pt)
MA (1) MA37764A1 (pt)
MX (1) MX2014014710A (pt)
PE (1) PE20142448A1 (pt)
PH (1) PH12014502789A1 (pt)
SG (1) SG11201407220YA (pt)
UA (1) UA109868C2 (pt)
WO (1) WO2013189864A1 (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014525932A (ja) 2011-08-15 2014-10-02 インターミューン， インコーポレイテッド リゾホスファチド酸レセプターアンタゴニスト
CA2869564A1 (en) * 2012-06-20 2013-12-27 F. Hoffmann-La Roche Ag N-aryltriazole compounds as lpar antagonists
KR102090231B1 (ko) 2013-03-15 2020-03-17 에피젠 바이오싸이언시즈, 아이엔씨. 질환의 치료에 유용한 헤테로환식 화합물
KR102433588B1 (ko) 2014-06-27 2022-08-19 우베 가부시키가이샤 할로겐 치환 헤테로환 화합물의 염
AR108838A1 (es) 2016-06-21 2018-10-03 Bristol Myers Squibb Co Ácidos de carbamoiloximetil triazol ciclohexilo como antagonistas de lpa
WO2019126084A1 (en) * 2017-12-19 2019-06-27 Bristol-Myers Squibb Company Isoxazole o-linked carbamoyl cyclohexyl acids as lpa antagonists
KR20200100713A (ko) 2017-12-19 2020-08-26 브리스톨-마이어스 스큅 컴퍼니 Lpa 길항제로서의 시클로헥실 산 트리아졸 아졸
JP2021506878A (ja) * 2017-12-19 2021-02-22 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｌｐａアンタゴニストとしてのシクロヘキシル酸イソキサゾールアジン
JP7202383B2 (ja) 2017-12-19 2023-01-11 ブリストル－マイヤーズ スクイブ カンパニー Ｌｐａアンタゴニストとしてのピラゾールｏ－架橋カルバモイルシクロヘキシル酸
KR20200100719A (ko) * 2017-12-19 2020-08-26 브리스톨-마이어스 스큅 컴퍼니 Lpa 길항제로서의 시클로헥실 산 트리아졸 아진
WO2019126087A1 (en) * 2017-12-19 2019-06-27 Bristol-Myers Squibb Company Cyclohexyl acid isoxazole azoles as lpa antagonists
CN111699180A (zh) 2017-12-19 2020-09-22 百时美施贵宝公司 作为lpa拮抗剂的吡唑n-连接的氨基甲酰基环己基酸
CN112041029A (zh) 2017-12-19 2020-12-04 百时美施贵宝公司 作为lpa拮抗剂的环己基酸吡唑唑类
MX2020006315A (es) 2017-12-19 2022-08-04 Bristol Myers Squibb Co Acidos carbamoil ciclohexilicos ligados a n triazol como antagonistas de acido lisofosfatidico (lpa).
JP7299892B2 (ja) 2017-12-19 2023-06-28 ブリストル－マイヤーズ スクイブ カンパニー Ｌｐａアンタゴニストとしてのシクロヘキシル酸ピラゾールアジン
KR20200100724A (ko) 2017-12-19 2020-08-26 브리스톨-마이어스 스큅 컴퍼니 Lpa 길항제로서의 이속사졸 n-연결된 카르바모일 시클로헥실 산
US11384055B2 (en) * 2017-12-29 2022-07-12 Biomarin Pharmaceutical Inc. Glycolate oxidase inhibitors for the treatment of disease
EP3852747B1 (en) * 2018-09-18 2023-05-31 Bristol-Myers Squibb Company Cycloheptyl acids as lpa antagonists
ES2946657T3 (es) * 2018-09-18 2023-07-24 Bristol Myers Squibb Co Acidos ciclopentílicos como antagonistas de LPA
KR20210060546A (ko) * 2018-09-18 2021-05-26 브리스톨-마이어스 스큅 컴퍼니 Lpa 길항제로서의 옥사비시클로 산
KR20220101137A (ko) * 2019-11-15 2022-07-19 길리애드 사이언시즈, 인코포레이티드 Lpa 수용체 길항제로서의 트라이아졸 카르바메이트 피리딜 설폰아미드 및 이의 용도
TW202344504A (zh) 2020-06-03 2023-11-16 美商基利科學股份有限公司 Lpa受體拮抗劑及其用途
WO2021247215A1 (en) 2020-06-03 2021-12-09 Gilead Sciences, Inc. Lpa receptor antagonists and uses thereof
WO2023107938A1 (en) 2021-12-08 2023-06-15 Gilead Sciences, Inc. Lpa receptor antagonists and uses thereof
TW202342017A (zh) 2022-02-25 2023-11-01 美商洛子峰生物有限公司 用於治療與ｌｐａ受體活性相關的病狀的化合物及組合物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200827346A (en) 2006-11-03 2008-07-01 Astrazeneca Ab Chemical compounds
GB2466121B (en) * 2008-12-15 2010-12-08 Amira Pharmaceuticals Inc Antagonists of lysophosphatidic acid receptors
GB2470833B (en) * 2009-06-03 2011-06-01 Amira Pharmaceuticals Inc Polycyclic antagonists of lysophosphatidic acid receptors
US20110065695A1 (en) 2009-09-11 2011-03-17 Jeremy Beauchamp Use of aminodihydrothiazines for the treatment or prevention of diabetes
GB2474748B (en) * 2009-10-01 2011-10-12 Amira Pharmaceuticals Inc Polycyclic compounds as lysophosphatidic acid receptor antagonists
WO2011159550A2 (en) 2010-06-14 2011-12-22 Amidra Pharmaceuticals, Inc. Lysophosphatidic acid receptor antagonist and uses thereof
WO2011159633A1 (en) * 2010-06-15 2011-12-22 Amira Pharmaceuticals, Inc. Inhalable formulations of lysophosphatdic acid receptor antagonists
CN103347510B (zh) * 2010-12-07 2015-11-25 艾米拉医药股份有限公司 溶血磷脂酸受体拮抗剂及其在治疗纤维化中的用途
WO2012138648A1 (en) * 2011-04-06 2012-10-11 Irm Llc Compositions and methods for modulating lpa receptors
JP2014525932A (ja) 2011-08-15 2014-10-02 インターミューン， インコーポレイテッド リゾホスファチド酸レセプターアンタゴニスト

Also Published As

Publication number Publication date
US9321738B2 (en) 2016-04-26
UA109868C2 (ru) 2015-10-12
PH12014502789A1 (en) 2015-02-09
AU2013279512A1 (en) 2014-10-16
CN104411692A (zh) 2015-03-11
KR20150021057A (ko) 2015-02-27
CL2014003243A1 (es) 2015-03-20
MA37764A1 (fr) 2016-01-29
EP2864300A1 (en) 2015-04-29
CA2869541A1 (en) 2013-12-27
IN2014DN09348A (pt) 2015-07-17
US20150133511A1 (en) 2015-05-14
CR20140525A (es) 2015-01-12
WO2013189864A1 (en) 2013-12-27
CO7131358A2 (es) 2014-12-01
BR112014030685A2 (pt) 2017-06-27
MX2014014710A (es) 2015-03-04
HK1206342A1 (en) 2016-01-08
IL236088A0 (en) 2015-02-01
PE20142448A1 (es) 2015-01-28
JP2015520202A (ja) 2015-07-16
EA201492285A1 (ru) 2015-04-30

Similar Documents

Publication Publication Date Title
SG11201407220YA (en) N-alkyltriazole compounds as lpar antagonists
SG11201407228PA (en) N-aryltriazole compounds as lpar antagonists
SG11201407229UA (en) Substituted pyrazole compounds as lpar antagonists
SG11201808990QA (en) Compositions for topical application of compounds
SG11201407534PA (en) New diazaspirocycloalkane and azaspirocycloalkane
SG11201908560SA (en) Heterocyclic compounds useful as dual atx/ca inhibitors
SG11201806745RA (en) Sulfonylureas and related compounds and use of same
SG11201805300QA (en) Heterocyclic compounds as immunomodulators
SG11201804170RA (en) Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders
SG11201407546QA (en) Novel ring-substituted n-pyridinyl amides as kinase inhibitors
SG11201809344QA (en) Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11201804152RA (en) Heterocyclic compounds as immunomodulators
SG11201408261UA (en) Syringe
SG11201804758QA (en) Aqueous pharmaceutical formulation comprising anti-pd-1 antibody avelumab
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201407669QA (en) Methods for improving safety of blood-brain barrier transport
SG11201408094YA (en) Neprilysin inhibitors
SG11201406973PA (en) Complement pathway modulators and uses thereof
SG11201809497RA (en) Processes for preparing phosphorodiamidate morpholino oligomers
SG11201809499UA (en) Processes for preparing phosphorodiamidate morpholino oligomers
SG11201407575PA (en) 5-amino[1,4]thiazines as bace 1 inhibitors
SG11201900558RA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11202000333UA (en) Bicyclic ketone compounds and methods of use thereof
SG11201805387RA (en) Meta-azacyclic amino benzoic acid derivatives as pan integrin antagonists
SG11201908691PA (en) Compounds and methods for the treatment of parasitic diseases